The Pharmaceutical Research and Manufacturers of America (PhRMA) will be honored as a Titan of Business & Philanthropy at the 2013 Leukemia Ball on March 23 at the Walter E. Washington Convention Center, organizers announced last week. The advocacy organization is being recognized for taking a lead in promoting safe, reliable medical technology and research. Since 2000, its member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.
PhRMA President and CEO John J. Castellani noted its support of The Leukemia & Lymphoma Society’s push for blood cancer cures and ensured PhRMA’s continued collaboration with The Society in searching for life-saving treatments for leukemia and lymphoma.
“Our shared goal in discovering new technologies and treatment options has created an extraordinary partnership in the fight against cancer,” he said. “PhRMA, which represents the leading biopharmaceutical research companies, is committed to the development of the life-saving and life-enhancing medicines for patients.”
PhRMA was originally founded as the Pharmaceutical Manufacturers Association in 1958 to support the industry. It was later renamed the Pharmaceutical Research and Manufacturers of America in 1994 as response to the increased use of medicine for treatment, importance and complexity of research and development, and focus on intellectual property issues including patent and data protection. The organization has over nine offices nationwide and one in Tokyo, Japan, and represents over 40 members including industry giants like Pfizer Inc, Johnson & Johnson and Glaxo SmithKline.
“The innovative research supported by PhRMA member companies is changing the landscape of cancer treatment, and in turn, helping LLS achieve its mission,” James H. Davis, Sr. co-Chair, Leukemia Ball, said. “Their commitment to helping patients live longer, healthier lives, is one that we at LLS share, and we are thankful to them for their support and partnership.”